TABLE 1.

Cohort demographics.

Patient characteristics
Age (years), median (range)	60 (27–82)
Sex, n (%)
Male	46 (66.7)
Female	23 (33.3)
Disease type, n (%)
B‐ALL	2 (2.9)
Intermediate/aggressive NHL	24 (34.8)
CLL	7 (10.1)
WM	16 (23.2)
Indolent NHL	15 (21.7)
Other (NLPHL, PCNSL, PTLD)	5 (7.3)
Treatment status at start of vaccine course, n (%)
On treatment	32 (46.4)
Completed <6 months prior	9 (13.0)
Completed >6 months prior	28 (40.6)
Treatment type, n (%)
Anti‐CD20 mAb	58 (84.1)
BTKi	16 (23.2)
CAR‐T	11 (15.9)

Note: Cohort demographics and clinical parameters, including disease diagnoses (B‐ALL, B‐cell acute lymphoblastic leukaemia; CLL, chronic lymphocytic leukaemia; NLPHL, nodular lymphocyte predominant Hodgkin lymphoma; NHL, non‐Hodgkin lymphoma; PTLD, post‐transplant lymphoproliferative disorder; PCNSL, primary central nervous system lymphoma; WM, Waldenström's macroglobulinaemia).